Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Bifunctional fusion protein targeting breast cancer cells active in murine model

July 31, 2002

Phase I/II results for VB2-011 encouraging

July 26, 2002

G17DT receives orphan drug status in gastric cancer

July 26, 2002

Safety review of BLP25 phase IIb trial

July 25, 2002

British Biotech and BresaGen terminate E21R development agreement

July 24, 2002

Oncophage designated orphan drug for metastatic melanoma

July 24, 2002

AltaRex receives positive opinion for OvaRex as orphan drug

July 12, 2002

Phase I/II follow-up data for GVAX lung cancer vaccine

July 2, 2002

Celgene expands Revimid development program

June 28, 2002

ImmunoGen faces development setbacks with two TAP products

June 27, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...